Thursday, July 4, 2013

Hydroxocobalamin acetate | Longavit B12 Ampoule



Longavit B12 Ampoule


"Hydroxocobalamin acetate 1.045 mg. ( Equivalent to hydroxocobalamin 1.00 mg)


Company Name


Memphis



Therapeutic Group


VITAMIN B12 PLAIN



Pharmaceutical form


Ampoule



Package


"carton box containing one ampoule (1 ml) & other of 3 ampoules (1 ml)."



Indications


"1- Pernicious anemia, both uncomplicated and

accompanied by nervous system involvement.

2- Dietary deficiency of Vitamin B12, occurring in strict

vegetarians and in their breast-fed infants. (Isolated

vitamin B12 deficiency is very rare).

3- Malabsorption of vitamin B12, resulting from structural

or functional damage to the stomach, where intrinsic

factor is secreted or to the ileum, where intrinsic factor

facilitates vitamin B12 absorption. These conditions

include tropical sprue, and nontropical sprue

(idiopathic steatorrhea, gluten-induced enteropathy).

Folate deficiency in these patients is usually more severe

than vitamin B12 deficiency.

4- Inadequate secretion of intrinsic factor, resulting from

lesions that destroy the gastric mucosa (ingestion of

corrosives, extensive neoplasia), and a number of

conditions associated with a variable degree of gastric

atrophy (such as multiple sclerosis, certain endocrine

disorders, iron deficiency, and subtotal gastrectomy).

Total gastrectomy always produces vitamin B12

deficiency. Structural lesions leading to vitamin B12

deficiency include regional ileitis, ileal resections,

malignancies, etc.

5- Competition for vitamin B12 by intestinal parasites or

bacteria. The fish tapeworm (Diphyilobothrium latum)

absorbs huge quantities of vitamin B12 and infested

patients often have associated gastric atrophy. The

blind-loop syndrome may produce deficiency of

Vitamin B12 or folate.

6- Inadequate utilization of vitamin B12.

This may occur if antimetabolites for the vitamin are

employed in the treatment of neoplasia.

7- For the Schilling Test."



Warning & Precautions


"WARNINGS: - Avoid the intravenous route. - Folic acid is not a substitute for vitamin B12 although it may improve vitamin B12 deficient megaloblastic anemia. Exclusive use of folic acid in treating vitamin B12 deficient megaloblastic anemia could result in progressive and irreversible neurologic damage. - Blunted or impeded therapeutic response to vitamin B12 may be due to such conditions as infection, uremia, drugs having bone marrow suppressant properties such as chloramphenicol, and concurrent iron or folic acid deficiency. PRECAUTIONS: General - The validity of diagnostic vitamin B12 or folic acid blood assays could be compromised by medications, and this should be considered before relying on such tests for therapy. - vitamin B12 is not a substitute for folic acid and since it might improve folic acid deficient megaloblastic anemia, indiscriminate use of vitamin B12 could mask the true diagnosis. - Hypokalemia and thrombocytosis could occur upon conversion of severe megaloblastic to normal erythropoiesis with B12 therapy. Therefore, serum potassium levels and the platelet count should be monitored carefully during therapy. - vitamin B12 deficiency may suppress the signs of polycythemia vera. Treatment with vitamin B12 may unmask this condition. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies of carcinogenicity, mutagenesis, or impairment of fertility have not been performed with hydroxocobalamin. Pregnancy: Teratogenic Effects: Pregnancy Category C: Animal reproduction studies have not been conducted with hydroxocobalamin. It is also not known whether hydroxocobalamin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Hydroxocobalamin should be given to a pregnant woman only if clearly needed.

























Product Type


Human



Dosage


"Protect from light.

- Parenteral drug products should be inspected visually

for particulate matter and discoloration prior to

administration, whenever solution and container permit.

- Hydroxocobalamin injection should be given only

intramuscularly.

- In patients with Addisonian Pernicious Anemia,

parenteral therapy with vitamin B12 is the recommended

method of treatment and will be required for the

remainder of the patient's life. Oral therapy is not dependable.

In other patients with vitamin B12 deficiency, the duration of

therapy and route of administration will depend upon the

cause and whether or not it is reversible.

- Confirmatory diagnostic studies should be performed

prior to initiating therapy, if possible, and the patient

should be followed with appropriate studies to

demonstrate hematologic improvement (Hgb,

hematocrit, RBC, reticulocyte count). A diagnostic trial

utilizing physiologic doses of vitamin B12 (1 mcg daily)

and observing daily reticulocyte counts after establishing

a baseline may also be performed. The observation of

reticulocytosis which usually occurs between the third

and tenth day of therapy confirms the diagnosis of

vitamin B12 deficiency.

- In seriously ill patients it may be advisable to administer

both vitamin B12 and folic acid while waiting the results

of distinguishing laboratory studies. It is not necessary to

withhold vitamin B12 therapy until the precise cause of

B12 deficiency is established since absorption studies can

be performed at any time.

- Serum potassium should be closely observed the first 48

hours and potassium should be administered if necessary.

Treatment of Vitamin B12 Deficiency

- Thirty mcg daily for 5 to 10 days followed by 100 to 200

mcg monthly injected intramuscularly.

- If the patient is critically ill, or has neurologic disease, an

infectious disease or hyperthyroidism, considerably higher

doses may be indicated. However, current data indicate

that the optimum obtainable neurologic response may

be expected with a dosage of vitamin B12 sufficient to

produce good hematologic response.

- Children may be given a total of 1 to 5 mg over a period

of 2 or more weeks in doses of 100 mcg, then 30 to 50

mcg every 4 weeks for maintenance.

- Patients who have normal intestinal absorption may be

treated with an oral therapeutic multivitamins

preparation, containing 15 mcg vitamin B12 daily.

- Schilling Test : The flushing dose is 1000 mcg. "



Adverse Reactions


"Mild transient diarrhea, itching, transitory exanthema,

feeling of swelling of entire body, and anaphylaxis.

A few patients may experience pain after injection of

hydroxocobalamin."



Contra Indications


Hypersensitivity to any component of this medication.



Drug Interactions


NA.






5 EgyDrug Index: Hydroxocobalamin acetate | Longavit B12 Ampoule Longavit B12 Ampoule "Hydroxocobalamin acetate 1.045 mg. ( Equivalent to hydroxocobalamin 1.00 mg) Com...

No comments:

Post a Comment